Table 2.
Antitumor Efficacy
| Variables | N = 88a |
|||||||
|---|---|---|---|---|---|---|---|---|
| All N = 88 | Second line n = 58 | Third line n = 22 | Fourth line n = 8 | |||||
| Objective response rate | ||||||||
| No. of patients with response | 24 | 18 | 3 | 3 | ||||
| % of patients (95% CI) | 27.3 | (18.3–37.8) | 31.0 | (19.5–44.5) | 13.6 | (2.9–34.9) | 37.5 | (8.5–75.5) |
| Disease control rate | ||||||||
| No. of patients with response | 78 | 52 | 18 | 8 | ||||
| % of patients (95% CI) | 88.6 | (80.1–94.4) | 89.7 | (78.8–96.1) | 81.8 | (59.7–94.8) | 100.0 | (63.1–100.0) |
| Best overall response, n (%) | ||||||||
| Complete response | 0 | 0 | 0 | 0 | ||||
| Partial response | 24 | (27.3) | 18 | (31.0) | 3 | (13.6) | 3 | (37.5) |
| Stable disease | 54 | (61.4) | 34 | (58.7) | 15 | (68.2) | 5 | (62.5) |
| Progressive disease | 8 | (9.1) | 4 | (6.9) | 4 | (18.2) | 0 | |
| Not evaluable | 2 | (2.3) | 2 | (3.4) | 0 | 0 | ||
Note: Tumor response assessed by clinical investigators.
CI, confidence interval.
a
Excluding four patients who did not have any target lesions.